A Study to Investigate the Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injections of PG-102 (MG12) in Healthy Adult and Obesity Participants.

Phase 1 Completed 102 enrolled ProGen. Co., Ltd.

RandomizedParallel-groupDouble-blindTreatment

Summary

This is a Phase 1, first-in-human (FIH), randomized, double-blind, placebo-controlled, combined single (Part A) multiple (Part B, C) ascending dose, phase 1 study to investigate the safety, tolerability and pharmacokinetic and pharmacodynamics following subcutaneous injections of PG-102(MG12) in healthy adult participants. This study will be conducted in 3 Parts (Part A, B and C), with up to 5 cohorts in each part.

Timeline

Start: 2024-03-04
Primary completion: 2025-02-05
Completion: 2025-02-05

Publications

Yang SI, Kim SW, Son KH, Lee SA, Kim JG, Roh JI, Sung YC. Bispecific GLP-1/GLP-2 agonism in advanced type 2 diabetes: preclinical characterization and a randomized, double-blind, placebo-controlled phase I trial. Nat Commun. 2026 Mar 24;17(1):4477. doi: 10.1038/s41467-026-71080-0.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PG-102(MG12)	Protein / enzyme biologic	15 mg	Subcutaneous
Subject	PG-102(MG12)	Protein / enzyme biologic	30 mg	Subcutaneous
Subject	PG-102(MG12)	Protein / enzyme biologic	60 mg	Subcutaneous

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injections of PG-102 (MG12) in Healthy Adult and Obesity Participants.

Summary

Timeline

Publications

Drugs

Indications